A Phase 1b Study Evaluating the Safety, Tolerability, and Immunogenicity of CMB305, a Lentiviral-Based Prime-Boost Vaccine Regimen, in Patients with Locally Advanced, Relapsed, or Metastatic Cancer Expressing NY-ESO-1-Reference-Cited by-同舟云学术

A Phase 1b Study Evaluating the Safety, Tolerability, and Immunogenicity of CMB305, a Lentiviral-Based Prime-Boost Vaccine Regimen, in Patients with Locally Advanced, Relapsed, or Metastatic Cancer Expressing NY-ESO-1

Published:2020-01-01 Issue:1 Volume:9 Page:
ISSN:2162-402X
Container-title:OncoImmunology
language:en
Short-container-title:OncoImmunology

Author:

Somaiah Neeta¹,Chawla Sant P.²,Block Matthew S.³,Morris John C.⁴,Do Khanh⁵,Kim Joseph W.⁶,Druta Mihaela⁷,Sankhala Kamalesh K.⁸,Hwu Patrick⁹,Jones Robin L.¹⁰¹¹¹²,Gnjatic Sacha¹³,Kim-Schulze Seunghee¹³,Tuballes Kevin¹³,Yishak Mahlet¹³,Lu Hailing¹⁴¹⁵,Yakovich Adam¹⁴¹⁶,Ter Meulen Jan¹⁴,Chen Michael¹⁴¹⁷,Kenney Richard T.¹⁴¹⁸,Bohac Chet¹⁴¹⁹,Pollack Seth M.²⁰

Affiliation:

1. Department of Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States

2. Sarcoma Oncology Center, Santa Monica, CA, United States

3. Department of Medical Oncology, Mayo Clinic, Rochester, MN, United States

4. Department of Medicine, University of Cincinnati College of Medicine, Cincinnati, OH, United States

5. Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United States

6. Department of Medical Oncology, Yale School of Medicine, New Haven, CT, United States

7. Medical Oncology, Moffitt Cancer Center, Tampa, FL, United States

8. Hematology/Oncology, Cedars-Sinai Medical Center, Beverly Hills, CA, United States

9. Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, United States

10. Seattle Cancer Care Alliance, Seattle, WA

11. Sarcoma Unit, Royal Marsden Hospital, London, UK

12. Sarcoma Clinical Trials, Institute of Cancer Research, London, UK

13. Human Immune Monitoring Center, Icahn School of Medicine at Mount Sinai, New York, NY, United States

14. Immune Design Corp., South San Francisco, CA, United States

15. Biomarkers and Diagnostics, Seattle Genetics, Inc, Bothell, WA, United States

16. Medical Affairs, Replimune Group, Inc, Woburn, MA, United States

17. *Sangamo Therapeutics, Inc., Brisbane, CA, United States

18. Clin Reg Biologics, LLC, Potomac, MD, United States

19. Macrogenics, Inc, Rockville, MD, United States

20. Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, United States

Funder

Merck & Co., Inc., Kenilworth, NJ USA

Publisher

Informa UK Limited

Subject

Oncology,Immunology,Immunology and Allergy

Link

https://www.tandfonline.com/doi/pdf/10.1080/2162402X.2020.1847846

Reference50 articles.

1. Therapeutic Cancer Vaccines

2. Therapeutic Cancer Vaccines

3. Cancer vaccines

4. Cancer vaccines: Enhanced immunogenic modulation through therapeutic combinations

5. Breast cancer vaccines: Heeding the lessons of the past to guide a path forward

Cited by 26 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Molecular characteristics and systemic treatment options of liposarcoma: A systematic review;Biomedicine & Pharmacotherapy;2024-09

2. NY‐ESO‐1 antigen: A promising frontier in cancer immunotherapy;Clinical and Translational Medicine;2024-09

3. Immunotherapy in Sarcoma: Current Data and Promising Strategies;American Society of Clinical Oncology Educational Book;2024-06

4. Immune profiling of dedifferentiated liposarcoma and identification of novel antigens for targeted immunotherapy;Scientific Reports;2024-05-16

5. Immune checkpoint inhibitors in sarcomas: a systematic review;Immuno-Oncology and Technology;2023-12